Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05461430Completed

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Role: collaborator

NCT06404034Unknown

Expanded Access to Gallium Maltolate (GaM)

Role: collaborator

NCT04566393Unknown

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Role: lead

NCT06539169Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Role: lead

NCT06140719Recruiting

xPedite: A Study to Expedite DIPG and DMG Research

Role: lead

NCT03793088Unknown

A Patient-Centric Platform Trial for Precision Oncology

Role: lead

NCT05052372Terminated

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Role: lead

NCT04321811Completed

Behavior, Environment And Treatments for Covid-19

Role: lead

All 8 trials loaded